Abstract
Multidrug resistance (MDR), caused by the overexpression of two membrane proteins, MDR1-Pgp and/or MRP, is a major obstacle in the chemotherapy of cancer. The proper laboratory diagnosis of clinical multidrug resistance is still an unresolved question, and this uncertainty, in a vicious cycle, does not allow the correct evaluation of the clinical relevance of the MDR phenomenon. Moreover, inefficient MDR diagnostics hinders the de velopment of effective resistance-modulation strategies. In this review, after describing the basic features of the MDR drug pump proteins, the currently employed diagnostic methods are discussed. We suggest that a quantitative, functional method developed in our laboratory may provide a major help in the laboratory assessment of cancer MDR.
Similar content being viewed by others
References
Endicott JA, Ling VZ: The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58:137–171, 1989.
Goldstein LJ, Pastan I, Gottesman MM: Multidrug resistance in human cancer. Critical Reviews in Oncology/Hematology 12:243–253, 1992.
Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427, 1993.
Broxterman HJ, Giaccone G, Lankelma J: Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Current Op Oncol 7:532–540, 1995
Sarkadi B, Müller M, Holló Zs; The Multidrug transporters -proteins of an ancient immune system. Immunology Letters 54:215–219, 1996.
Gottesman MM, Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263:12163–12166, 1988.
Cole SPC, Bhardwaj G, Gerlach JH, et al: Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science 258:1650–1654, 1992.
Leier I, Jedlitschky G, Buchholz U, et al: MRP gene encodes an ATP-dependent export pump for Leukotriene C4 and structuraly related conjugates. J Biol Chem 269:27807–278010, 1994.
Zaman GJR, Versantvoort CHM, Smit JJM, et al: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53:1747–1750, 1993.
Kartenbeck J, Leuschner U, Mayer R, et al: Absence of the Canalicular Isoform of the MRP Gene-Encoded Conjugate Export Pump From the Hepatocytes in Dubin-Johnson Syndrome. Hepatology 23:1061–1066, 1966.
Schinkel AH, Smit JJ, van Teilingen O, et al: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502, 1994.
Schinkel AH, Mayer U, Wagenaar E, et al: P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94:4028–4033, 1997.
Filipits M, Suchomel RW, Zöcherbauer S, et al: Clinical relevance of drug resistance genes in malignant diseases. Leukemia 10, Suppl: S10-S17, 1996.
Higgins CF: ABC transporters-from microorganisms to man. Annu Rev Cell Biol 8:67–113, 1992.
Borst P, Kool M, Ever s R: Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Seminars in Cancer Biology 8:205–213, 1997.
Jedlitschky G, Leier I, Buchholz U, et al: ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833–4836, 1994.
Müller M, Meijer C, Zaman GJR, et al: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033–13037, 1994.
Versantvoort CHM, Broxterman, HJ, Bagrij T, et al: Regulation by gluthatione of drug transport in multidrug resistant human lung tumour cell lines overexpressing MRP. Br J Cancer 72:82–89, 1995
Sarkadi B, Müller M: Search for specific inhibitors of multidrug resistance in cancer. Seminars in Cancer Biology 8:171–182, 1997.
Raderer M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553–3563, 1993.
Sikic BI, Fisher GA, Lum BL, et al: Clinical reversal of multidrug resistance. Cancer Treat Res 73:149–65, 1994.
Fisher GA, Lum BL, Sikic BI: The reversal of multidrug resistance. Cancer Treat Res 78:5–70, 1995.
Ford JM: Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A:991–1001, 1996.
Sonneveld P: Reversal of multidrug resistance in acute myeloid leukemia and other haematological malignancies. Eur J Cancer 32A: 1062–1069, 1996.
Broxtermann HJ, Lankelma J, Pinedo HM: How to Probe Clinical Tumour Samples for P-glycoprotein and Multidrug Resistance-associated Protein. Eur J Cancer 32A:1024–1033, 1996.
Beck WT, Grogan TM: Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 11:1107–1109, 1997.
Piwnica-Worms D, Rao VV, Kronauge JF, et al: Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 34(38):12210–12220, 1995.
Taki J, Sumiya H, Asada N, et al: Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 39:1179–84, 1998
Kostakoglu L, Guc D, Canpinar H, et al: P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologie malignancy. J Nucl Med 39:1191–1197, 1998.
Noonan KE, Beck C, Holzmayer TA, et al: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Nat Acad Sci 87:7160–7164, 1990.
Okochi E, Iwahashi T, Tsuoro T: Monoclonal antibodies specific for P-glycoprotein. Leukemia 11:1119–1123, 1997.
Flens MJ, Izquierdo MA, Scheffer GL et al: Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug resistant tumor cells by monoclonal antibodies. Cancer Res 51:4557–4563, 1994.
Beck WT, Grogan TM, Willman CL et al: Methods to Detect P-Glycoprotein-associated Multidrug Resistance in Patients Tumors: Consensus Recommendations. Cancer Res 56:3010–3020, 1996.
Marie JP, Legrand O, Perrot JY, et al: Measuring Multidrug Resistance Expression in Human Malignancies: Elaboration of Consensus Recommendations. Seminars in Hematology 34, Suppl 5:63–71, 1997.
Pétriz J, García-Lopez J: Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 11:1124–1130, 1997.
Kuttesch JF Jr: Multidrug resistance in pediatrie oncology. Invest New Drugs 14:55–67, 1996.
Brotherick I, Shenton BK, Egan M, et al: Examination of Multidrug Resistance in Cell Lines and Primary Breast Tumours by Flow Cytometry. Eur J Cancer 32A:2334–2341, 1996.
Mechetner EB, Schott B, Morse BS, et al: P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Nat Acad Sci 94:12908–12913, 1997.
Chevillard S, Vielh P, Validire P, et al: French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. Leukemia 11:1095–1106, 1997.
Feller N, Kuiper CM, Lankelma J, et al: Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 72:543–549, 1995.
Leith CP, Chen IM, Kopecky KJ, et al: Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 86:2329–2342, 1995.
Twentyman PR, Rhodes T, Rayner S: A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance pheno-types. Eur J Cancer 30A: 1360–1369, 1994.
Homolya L, Holló Z, Germann UA, et al: Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268:21493–21496, 1993.
Holló Zs, Homolya L, Davis CW,et al: Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191:384–388, 1994.
Homolya L, Hollo Z, Müller M, et al: A new method for quantitative assessment of P-glycoprotein-related multidrug resistance in turnout cells. Br J Cancer 73:849–855, 1996.
Feller N, Broxterman HJ, W hrer DCR, et al: ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 368:385–388, 1995.
Holló Zs, Homolya L, Hegedűs T, et al: Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 383:99–104, 1996.
Holló Zs, Homolya L, Hegedűs T, et al: Parallel functional and immunological detection of human multidrug resistance Proteins, P-glycoprotein and MRP1. Anticancer Res 18:2981–2988, 1988.
Legrand O, Simonin G, Perrot H, et al: Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91:4480–8, 1998.
Legrand O, Simonin G, Zittoun R, et al: Both P-gp and MRP contribute to drug resistance in AML. Leukemia 12:1327–1328, 1998.
Raspadori D, Lauria F, Ventura A, et al: Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leukemia Res 21:603–607, 1997
Boekhorst PA, Leeuw K, Schoester M, et al: Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82:3157–3162,1993
Nuessler V, Gullis E, Pelka-Fleischer R, et al: Expression and functional activity of P-glycoprotein in adult acute myeloge-nous leukemia patients. Ann Haematol 75:17–26, 1997
Martinez A, San Miguel JF, Valverde B, et al: Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics. Ann Haematol 75:81–86, 1997
Del Poeta G, Stasi R, Aronica G, et al: Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 87:1997–2004, 1996
Lamy T, Goasguen J, Mordetet E, et al: P-Glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 8:1879–1883, 1994
Heuvel-Eibrink MM, Holt B, te Boekhorst PA et al: MDR1 expresssion is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. British Journal of Haematology 99: 76–83, 1997
Wattel E, Lepelley P, Merlat A, et al: Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. Leukemia 9:1870–1874, 1995
Schneider E, Cowan KH, Bader H, et al: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186–193, 1995.
Kuss BJ, Deeley RG, Cole SP, et al: The biological significance of the multidrug resistance gene MRP in inversion 16 leuke-mias. Leuk Lymphoma 20:357–364, 1996
Salmon SE, Dalton WS, Grogan TM, et al: Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44–50, 1991.
Watanabe T, Tsuge H, Oh-Hara T, et al: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34:235–41, 1995.
Kornblau SM, Estey E, Madden T, et al: Phase I study of Mitoxantrone plus Etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15:1796–1802, 1997.
Wattel E, Solary E, Hecquet B, et al: Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 102:1015–1024, 1998.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gergely, S., Katalin, J., Ferenc, A. et al. Diagnostics of multidrug resistance in cancer. Pathol. Oncol. Res. 4, 251–257 (1998). https://doi.org/10.1007/BF02905214
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02905214